The stock of Windtree Therapeutics (NAS:WINT, 30-year Financials) shows every sign of being significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $2.34 per share and the market cap of $61.4 million, Windtree Therapeutics stock gives every indication of being significantly overvalued. GF Value for Windtree Therapeutics is shown in the chart below.
Because Windtree Therapeutics is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth.
Link: These companies may deliever higher future returns at reduced risk.
Investing in companies with poor financial strength has a higher risk of permanent loss of capital. Thus, it is important to carefully review the financial strength of a company before deciding whether to buy its stock. Looking at the cash-to-debt ratio and interest coverage is a great starting point for understanding the financial strength of a company. Windtree Therapeutics has a cash-to-debt ratio of 5.55, which is in the middle range of the companies in Biotechnology industry. GuruFocus ranks the overall financial strength of Windtree Therapeutics at 5 out of 10, which indicates that the financial strength of Windtree Therapeutics is fair. This is the debt and cash of Windtree Therapeutics over the past years:
It is less risky to invest in profitable companies, especially those with consistent profitability over long term. A company with high profit margins is usually a safer investment than those with low profit margins. Windtree Therapeutics has been profitable 0 over the past 10 years. Over the past twelve months, the company had a revenue of $0 million and loss of $2.28 a share. Its operating margin is 0.00%, which ranks in the bottom 10% of the companies in Biotechnology industry. Overall, the profitability of Windtree Therapeutics is ranked 1 out of 10, which indicates poor profitability. This is the revenue and net income of Windtree Therapeutics over the past years:
Growth is probably one of the most important factors in the valuation of a company. GuruFocus' research has found that growth is closely correlated with the long-term performance of a company's stock. If a company's business is growing, the company usually creates value for its shareholders, especially if the growth is profitable. Likewise, if a company's revenue and earnings are declining, the value of the company will decrease. Windtree Therapeutics's 3-year average revenue growth rate is in the bottom 10% of the companies in Biotechnology industry. Windtree Therapeutics's 3-year average EBITDA growth rate is 79%, which ranks better than 97% of the companies in Biotechnology industry.
Another way to evaluate a company's profitability is to compare its return on invested capital (ROIC) to its weighted cost of capital (WACC). Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the ROIC is higher than the WACC, it indicates that the company is creating value for shareholders. Over the past 12 months, Windtree Therapeutics's ROIC was -28.34, while its WACC came in at 0.76. The historical ROIC vs WACC comparison of Windtree Therapeutics is shown below:
In conclusion, the stock of Windtree Therapeutics (NAS:WINT, 30-year Financials) shows every sign of being significantly overvalued. The company's financial condition is fair and its profitability is poor. Its growth ranks better than 97% of the companies in Biotechnology industry. To learn more about Windtree Therapeutics stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
